JP2009518410A5 - - Google Patents

Download PDF

Info

Publication number
JP2009518410A5
JP2009518410A5 JP2008544428A JP2008544428A JP2009518410A5 JP 2009518410 A5 JP2009518410 A5 JP 2009518410A5 JP 2008544428 A JP2008544428 A JP 2008544428A JP 2008544428 A JP2008544428 A JP 2008544428A JP 2009518410 A5 JP2009518410 A5 JP 2009518410A5
Authority
JP
Japan
Prior art keywords
dsrna
medicament according
vaccine
animal
avian influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/046356 external-priority patent/WO2007067517A2/en
Publication of JP2009518410A publication Critical patent/JP2009518410A/ja
Publication of JP2009518410A5 publication Critical patent/JP2009518410A5/ja
Pending legal-status Critical Current

Links

JP2008544428A 2005-12-07 2006-12-06 インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ Pending JP2009518410A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74290605P 2005-12-07 2005-12-07
US75289805P 2005-12-23 2005-12-23
US79323906P 2006-04-20 2006-04-20
PCT/US2006/046356 WO2007067517A2 (en) 2005-12-07 2006-12-06 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013013055A Division JP2013075920A (ja) 2005-12-07 2013-01-28 インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ

Publications (2)

Publication Number Publication Date
JP2009518410A JP2009518410A (ja) 2009-05-07
JP2009518410A5 true JP2009518410A5 (enExample) 2010-02-25

Family

ID=38123418

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008544428A Pending JP2009518410A (ja) 2005-12-07 2006-12-06 インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
JP2013013055A Pending JP2013075920A (ja) 2005-12-07 2013-01-28 インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013013055A Pending JP2013075920A (ja) 2005-12-07 2013-01-28 インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ

Country Status (6)

Country Link
US (3) US7943147B2 (enExample)
EP (1) EP1957101A4 (enExample)
JP (2) JP2009518410A (enExample)
AU (1) AU2006322073A1 (enExample)
CA (1) CA2632516C (enExample)
WO (1) WO2007067517A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137154A1 (en) * 2003-05-16 2005-06-23 Hemispherx Biopharma Treating server acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
JP2009518410A (ja) * 2005-12-07 2009-05-07 へミスフェリックス・バイオファーマ インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
WO2008156753A1 (en) * 2007-06-18 2008-12-24 Hemispherx Biopharma Early intervention of viral infections with immune activators
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
BRPI0907515A2 (pt) * 2008-02-15 2015-07-28 Hemispherx Biopharma Inc Agonista seletivo de receptor 3 do tipo toll
US20110110979A1 (en) * 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9603919B2 (en) 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
MX2022000134A (es) 2019-07-02 2022-05-19 Na Vaccine Inst Nuevo ácido ribonucleico y composición farmacéutica basada en el mismo.
EP4023244A4 (en) * 2019-08-28 2023-11-01 NA Vaccine Institute INFLUENZA VACCINE COMPOSITION BASED ON A NOVEL NUCLEIC ACID

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
RU2390351C2 (ru) 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
JP2009518410A (ja) * 2005-12-07 2009-05-07 へミスフェリックス・バイオファーマ インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
BRPI0808637A2 (pt) 2007-03-05 2014-08-05 Univ Utah State Agonista restritivo do receptor 3 similar a toll (tlr3)

Similar Documents

Publication Publication Date Title
JP6378380B2 (ja) ワクチン組成物
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
JP2009518410A5 (enExample)
JP2013516450A5 (enExample)
JP2009511084A5 (enExample)
JP2009539965A5 (enExample)
Hayden Advances in antivirals for non‐influenza respiratory virus infections
Cai et al. 14-Deoxy-11, 12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A (H5N1) influenza viruses
Gasparini et al. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza Part II: Future compounds against influenza virus
JP2013518107A5 (enExample)
JP2012502037A5 (enExample)
JP2017524682A5 (enExample)
Budimir et al. Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration
Deng et al. Antiviral activity of Folium isatidis derived extracts in vitro and in vivo
CN113304166A (zh) 核苷类化合物在治疗冠状病毒感染性疾病中的用途
JP2012001565A5 (enExample)
JP2010270130A5 (enExample)
CN101744805B (zh) 穗花杉双黄酮作为唯一活性成分在制备治疗乙肝病毒药物中的应用
JP2016520077A5 (enExample)
Zheng et al. In vitro screening of traditional Chinese medicines compounds derived with anti-encephalomyocarditis virus activities
JP2009518410A (ja) インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
JP2010528053A (ja) インフルエンザ感染症を治療するための物質および方法
JP2014512353A5 (enExample)
Andreev et al. Promising compounds from natural sources against COVID-19
Cristea Genomic signal analysis of pathogen variability